Chemistry:Naptumomab estafenatox
From HandWiki
 Schematic image of naptumomab estafenatox. VH, VL: variable (antigen binding) domains of antibody fragment | |
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Mouse |
| Target | 5T4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C3255H5025N855O1050S18 |
| Molar mass | 73513.02 g·mol−1 |
  (what is this?) (verify) | |
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma.[2]
Mechanism of action
Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.[4]
See also
- Nacolomab tafenatox, a drug with a similar chemical structure and mechanism
References
- ↑ "Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer". Journal of Clinical Oncology 27 (25): 4116–23. September 2009. doi:10.1200/JCO.2008.20.2515. PMID 19636016.
- ↑ Clinical trial number NCT00420888 for "ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma" at ClinicalTrials.gov
- ↑ "Naptumomabum estafenatoxum". WHO Drug Information 20 (4): 291. 2006. http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf.
- ↑ "Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin". Current Oncology Reports 16 (2): 370. February 2014. doi:10.1007/s11912-013-0370-0. PMID 24445502.
 |  |
